KYSE-30 Cells

KYSE-30 is a well-differentiated human esophageal squamous cell carcinoma (ESCC) cell line derived from a primary tumor in an adult patient. As part of the KYSE series, this cell line was established to study the molecular and cellular characteristics of esophageal cancer. KYSE-30 cells are notable for their rapid proliferation, with a doubling time of 20.8 hours, making them a robust model for in vitro cancer research. These cells grow predominantly as adherent monolayers, displaying a characteristic polygonal shape and uniform appearance under phase-contrast microscopy. Their growth pattern is typical of epithelial-derived cancer cells, forming tightly packed colonies with a tendency to pile up in a disorganized manner, reflecting the invasive nature of the tumor from which they were derived.

Genetically, KYSE-30 is significant for its alterations in key tumor suppressor genes. The cell line exhibits a wild-type configuration for the p16 (INK4a) and p15 (INK4b) genes, but it carries a notable point mutation in the p16 gene that results in a premature stop codon, leading to a truncated, non-functional protein. This mutation likely contributes to the loss of cell cycle control, promoting the unchecked proliferation characteristic of cancer cells. The retention of the wild-type p15 gene, however, suggests that p16 gene alterations play a more critical role in the oncogenesis of KYSE-30, which may be relevant in studies focusing on the differential roles of these genes in cancer.

KYSE-30 is tumorigenic, as demonstrated by its ability to form tumors when injected into athymic nude mice, making it an excellent model for in vivo studies of ESCC. The histological examination of tumors formed by KYSE-30 cells shows characteristics similar to the original squamous cell carcinoma, providing a faithful representation of the disease. This cell line is invaluable for research into the mechanisms of tumorigenesis, the genetic and epigenetic changes driving esophageal cancer, and the development of targeted therapies, although it is not suitable for therapeutic or in vivo applications.